Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. März 2023 03:00 ET | Quelle: Anaveon

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting

BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...
10. September 2022 03:00 ET | Quelle: Anaveon

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...
08. April 2022 13:00 ET | Quelle: Anaveon

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

- ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...
16. Dezember 2021 02:00 ET | Quelle: Anaveon

Anaveon to raise CHF 110 million in oversubscribed Series B financing

- Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...